Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03865082 · ClinicalTrials.gov registry record · Phase 2

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

A Phase 2 study of Solid Tumor, sponsored by Idera Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
3
Study locations

NCT03865082 is a Phase 2 study of Solid Tumor that is active but no longer recruiting, run by Idera Pharmaceuticals. The registered enrollment target is 30 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03865082, a Phase 2 study of Solid Tumor, is active but no longer recruiting, sponsored by Idera Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.

Conditions Studied

Solid Tumor

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Tilsotolimod

Study Locations (3)

Arizona

  • Banner University Medical Center Tucson Campus - Tucson

California

  • University of Southern California/ Hoag Hospital Presbyterian - Newport Beach

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-10-29
Est. Completion 2022-04
Phase Phase 2

Sponsor

Idera Pharmaceuticals

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03865082

The ClinicalTrials.gov registry entry for NCT03865082 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT03865082 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Texas.

Frequently Asked Questions

What is clinical trial NCT03865082 about?

NCT03865082 is a clinical study titled "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)". A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.

What is the current status of trial NCT03865082?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-29. Estimated completion is 2022-04.

What conditions does trial NCT03865082 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT03865082?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Tilsotolimod (DRUG).

Who is sponsoring clinical trial NCT03865082?

This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03865082 being conducted?

This trial has 3 study locations across Arizona, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.